{"disease":{"id":"sar","name":"sar"},"drugs":{"marketed":[{"drug_id":"eribulin","indication_name":"Liposarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halaven","generic_name":"ERIBULIN","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"Microtubule Inhibitor","quality_score":71,"revenue":"400","mechanism":"Halaven works by binding to tubulin beta, disrupting microtubule dynamics and leading to cell death."},{"drug_id":"paclitaxel","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"nab-paclitaxel","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"nabpaclitaxel","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"dactinomycin","indication_name":"Rhabdomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosmegen","generic_name":"DACTINOMYCIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Actinomycin [EPC]","quality_score":65,"revenue":null,"mechanism":"Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models."},{"drug_id":"dactinomycin","indication_name":"Ewing Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosmegen","generic_name":"DACTINOMYCIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Actinomycin [EPC]","quality_score":65,"revenue":null,"mechanism":"Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models."},{"drug_id":"voriconazole","indication_name":"Serious fungal infections caused by Scedosporium apiospermum and Fusarium species","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"voriconazole","indication_name":"Scedosporiosis and Fusariosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Soft Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl359744","indication_name":"Metastatic Bone Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXORUBICIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"topoisomerase II","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA, inhibiting nucleotide replication, and forming DNA-cleavable complexes with topoisomerase II."},{"drug_id":"chembl-chembl428647","indication_name":"AIDS-related Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PACLITAXEL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Microtubule Inhibitor [EPC]","quality_score":37,"revenue":null,"mechanism":null},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic synovial sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic soft tissue sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"interferon-alfa-2b","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ropivacaine","indication_name":"Anesthesia for cesarean section","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Naropin","generic_name":"ROPIVACAINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Amide Local Anesthetic","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"tasonermin","indication_name":"Sarcoma of soft tissue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Beromun","generic_name":"TASONERMIN","company_name":"Boehringer Ingelheim International GmbH","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"oncovin","indication_name":"Rhabdomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oncovin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"hydrocortisone-succinate","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"vincristin","indication_name":"Rhabdomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vincristin","company_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"yondelis","indication_name":"Leiomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yondelis","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"yondelis","indication_name":"Liposarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yondelis","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"yondelis","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yondelis","company_name":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src, Nuclear receptor subfamily 1 group I member 2","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"daunorubicin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Daunorubicin Hydrochloride","generic_name":"daunorubicin","company_name":"Meiji Seika Pharma Co., Ltd","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"trabectedin","indication_name":"Leiomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yondelis","generic_name":"TRABECTEDIN","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth."},{"drug_id":"trabectedin","indication_name":"Liposarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yondelis","generic_name":"TRABECTEDIN","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth."},{"drug_id":"trabectedin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yondelis","generic_name":"TRABECTEDIN","company_name":"Janssen Prods","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase Src","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Yondelis works by binding to DNA and causing interstrand crosslinks, thereby inhibiting cancer cell growth."},{"drug_id":"hydrocortisone-acetate","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"cefotaxime","indication_name":"Cesarean Section Infection Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"itraconazole","indication_name":"Fungal Infection due to Fusarium Solani","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"itraconazole","indication_name":"Fusarium infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Cesarean Section Infection Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"olaratumab","indication_name":"Sarcoma of soft tissue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lartruvo","generic_name":"OLARATUMAB","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Platelet-derived growth factor receptor alpha","drug_class":"Platelet-derived Growth Factor Receptor alpha Antagonist","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"bupivacaine","indication_name":"Anesthesia for cesarean section","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride And Epinephrine","generic_name":"BUPIVACAINE","company_name":"Innocoll","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"Amide Local Anesthetic","quality_score":69,"revenue":null,"mechanism":"Bupivacaine works by blocking nerve impulses to prevent pain signals from reaching the brain."},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Kaposi Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"permethrin","indication_name":"Infestation by Sarcoptes scabiei var hominis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elimite","generic_name":"PERMETHRIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrethroid [EPC]","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"phenothrin","indication_name":"Infestation by Sarcoptes scabiei var hominis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sumithrin","generic_name":"PHENOTHRIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"phenothrin","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"piperacillin","indication_name":"Cesarean Section Infection Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"daunorubicine","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Daunorubicine","company_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","drug_phase":"discontinued","molecular_target":"Multidrug resistance-associated protein 6, 72 kDa type IV collagenase, ATP-binding cassette sub-family G member 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic soft tissue sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"doxorubicin-hydrochloride","indication_name":"Metastatic bone sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxorubicin Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, nucleotide bases","drug_class":"Anthracycline topoisomerase inhibitor","quality_score":70,"revenue":null,"mechanism":"Doxorubicin intercalates nucleotide bases and interacts with topoisomerase II to form DNA-cleavable complexes, inhibiting DNA/RNA replication."},{"drug_id":"gleevec","indication_name":"Dermatofibrosarcoma protuberans","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gleevec","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma, ATP-binding cassette sub-family G member 2, ATP-dependent RNA helicase DDX3X","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tretinoin","indication_name":"Kaposi's Sarcoma Skin Lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Retin-A","generic_name":"TRETINOIN","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Nuclear receptor ROR-beta","drug_class":"Retinoid [EPC]","quality_score":58,"revenue":null,"mechanism":"Tretinoin works by binding to and activating nuclear receptors, which helps to regulate cell growth and differentiation."},{"drug_id":"hydroxydaunorubicin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bupivacain","indication_name":"Anesthesia for cesarean section","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bupivacain","company_name":"Sisli Hamidiye Etfal Training and Research Hospital","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Cytochrome P450 2D6, Potassium channel subfamily K member 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"temodal","indication_name":"Ewing's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Temodal","company_name":"Armando Santoro, MD","drug_phase":"phase_1","molecular_target":"","drug_class":"","quality_score":3,"revenue":null,"mechanism":null},{"drug_id":"mifamurtide","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mepact","generic_name":"MIFAMURTIDE","company_name":"Takeda France SAS","drug_phase":"marketed","molecular_target":"Nucleotide-binding oligomerization domain-containing protein 2","drug_class":"mifamurtide","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"lignocaine","indication_name":"Infestation by Sarcoptes scabiei var hominis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lignocaine","company_name":"University of Malaya","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tazemetostat","indication_name":"Epithelioid sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"vinblastin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vinblastin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ropivacain","indication_name":"Anesthesia for cesarean section","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ropivacain","company_name":"University Hospital, Basel, Switzerland","drug_phase":"marketed","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naropine","indication_name":"Anesthesia for cesarean section","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naropine","company_name":"Rigshospitalet, Denmark","drug_phase":"phase_1","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lidocaine-hydrochloride","indication_name":"Infestation by Sarcoptes scabiei var hominis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lignospan Forte","generic_name":"Lidocaine Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"neuronal membrane ionic channels","drug_class":"local anesthetic, amide type","quality_score":68,"revenue":null,"mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction."},{"drug_id":"methylprednisolone","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"part-c-met097","indication_name":"Treatment of Mast Cell Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."},{"drug_id":"votrient","indication_name":"Sarcoma of soft tissue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Votrient","company_name":"Tracon Pharmaceuticals Inc.","drug_phase":"marketed","molecular_target":"Bone morphogenetic protein receptor type-1B, Cyclin-dependent kinase 11A, Cyclin-dependent kinase 11B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"busilvex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busilvex","company_name":"medac GmbH","drug_phase":"phase_2","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"triamcinolone","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"naropeine","indication_name":"Anesthesia for cesarean section","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Naropeine","company_name":"University Hospital, Rouen","drug_phase":"phase_3","molecular_target":"Potassium channel subfamily K member 3, Sodium channel protein type 1 subunit alpha, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"alitretinoin","indication_name":"Kaposi's Sarcoma Skin Lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Panretin","generic_name":"ALITRETINOIN","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Retinoic acid receptor beta","drug_class":"Retinoid [EPC]","quality_score":10,"revenue":null,"mechanism":"Panretin works by binding to retinoic acid receptors in the skin, which helps to slow down the growth of cancer cells."},{"drug_id":"cefoxitin","indication_name":"Cesarean Section Infection Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Rhabdomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"imatinib","indication_name":"Dermatofibrosarcoma protuberans","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleevec","generic_name":"imatinib","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Kinase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation."},{"drug_id":"vincristine","indication_name":"Rhabdomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"vincristine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"dactinomycin","indication_name":"Ewing's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosmegen","generic_name":"DACTINOMYCIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Actinomycin [EPC]","quality_score":65,"revenue":null,"mechanism":"Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models."},{"drug_id":"dactinomycin","indication_name":"Rhabdomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosmegen","generic_name":"DACTINOMYCIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Actinomycin [EPC]","quality_score":65,"revenue":null,"mechanism":"Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models."},{"drug_id":"crotamiton","indication_name":"Infestation by Sarcoptes scabiei var hominis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eurax","generic_name":"CROTAMITON","company_name":"Journey","drug_phase":"marketed","molecular_target":"","drug_class":"crotamiton","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"levobupivacaine","indication_name":"Anesthesia for cesarean section","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chirocain","generic_name":"LEVOBUPIVACAINE","company_name":"Purdue Pharma Lp","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"levobupivacaine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"busulfan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Busulfex","generic_name":"busulfan","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Busulfex works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"prednisone","indication_name":"Symptomatic sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"temozolomide","indication_name":"Ewing's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temodar","generic_name":"temozolomide","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Temodar works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"doxorubicin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"doxorubicin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"doxorubicin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"doxorubicin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"chembl-chembl3414621","indication_name":"Epithelioid sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"TAZEMETOSTAT","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of an enzyme called EED, which is involved in the production of proteins that promote cancer growth."},{"drug_id":"methotrexate","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trexall","generic_name":"methotrexate","company_name":"Generic (originally Lederle Laboratories)","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"Antifolate, DMARD","quality_score":55,"revenue":null,"mechanism":"Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune)."},{"drug_id":"methotrexat","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methotrexat","company_name":"Biocad","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunomycin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tazverik","indication_name":"Epithelioid sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tazverik","company_name":"Edwin Posadas, MD","drug_phase":"discontinued","molecular_target":"Polycomb protein EED, Histone-lysine N-methyltransferase EZH1, Histone-lysine N-methyltransferase EZH2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"lidocain","indication_name":"Infestation by Sarcoptes scabiei var hominis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocain","company_name":"Bayer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Kaposi's sarcoma associated with AIDS","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Osteosarcoma of bone","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Soft or Connective Tissue Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulfex","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"busulfex","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"busulphan","indication_name":"Autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Busulphan","company_name":"University of Birmingham","drug_phase":"discontinued","molecular_target":"Matrix metalloproteinase-9","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolon","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Kaposi's sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xylocain","indication_name":"Infestation by Sarcoptes scabiei var hominis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xylocain","company_name":"Saint-Joseph University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bupivacaine-hydrochloride-and-epinephrine","indication_name":"Anesthesia for cesarean section","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bupivacaine Hydrochloride","generic_name":"Bupivacaine Hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nerve sodium channels","drug_class":"Amide-type local anesthetic","quality_score":10,"revenue":null,"mechanism":"Bupivacaine blocks nerve impulse generation and conduction by increasing electrical excitation threshold and slowing action potential rise."},{"drug_id":"betamethasone","indication_name":"Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"tazemetostat","indication_name":"Epithelioid Sarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Rhabdomyosarcoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone-phosphate","indication_name":"Symptomatic Sarcoidosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"ontorpacept-tti-621","indication_name":"Leiomyosarcoma","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ontorpacept (TTI-621)","generic_name":"ontorpacept-tti-621","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Ontorpacept (TTI-621) will be administered by intravenous infusion.","quality_score":null,"revenue":null,"mechanism":"Ontorpacept (TTI-621) will be administered by intravenous infusion."},{"drug_id":"chlorthalidone","indication_name":"Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTHALIDONE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/Cl− cotransporter","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":123,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT04958954","title":"Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":50000000,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT06199934","title":"Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":19853610,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06130345","title":"Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran","phase":"","overall_status":"COMPLETED","enrollment_count":15196685,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT04738331","title":"Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database","phase":"","overall_status":"UNKNOWN","enrollment_count":10000000,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04653844","title":"RT-PCR Database Analysis for COVID-19 Infections and Re-infection","phase":"","overall_status":"UNKNOWN","enrollment_count":7000000,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05020145","title":"COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1277747,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05933304","title":"A Study of the Effectiveness of Moderna COVID-19 Vaccine","phase":"","overall_status":"COMPLETED","enrollment_count":927004,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT05321433","title":"Tobacco Use and the Risk of COVID-19 and Adverse Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":757585,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04838795","title":"Sisonke (Together): OPEN LABEL TRIAL COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":477102,"lead_sponsor_name":"Wits Health Consortium (Pty) Ltd","has_results":false},{"nct_id":"NCT06160128","title":"Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)","phase":"","overall_status":"RECRUITING","enrollment_count":400000,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT04655456","title":"Feasibility of Estimating the Prevalence of Malnutrition, Frailty and Sarcopenia in Older People in UK Biobank, Cross-sectional Study: A Study Protocol","phase":"","overall_status":"COMPLETED","enrollment_count":381000,"lead_sponsor_name":"University of Manchester","has_results":false},{"nct_id":"NCT05186571","title":"Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old","phase":"","overall_status":"UNKNOWN","enrollment_count":350000,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04471701","title":"Italian Web-based Cross-sectional Survey on COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"Institute of Biomedical Technologies-National Research Council, Italy","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT03978039","title":"National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group","phase":"","overall_status":"RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT04756609","title":"Systematic Offer of Nurse-Driven Screening for COVID-19 in Emergency Departments in the Paris Metropolitan Area, DEPIST-COVID","phase":"NA","overall_status":"COMPLETED","enrollment_count":138352,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04351503","title":"A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":126586,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT05366322","title":"A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults","phase":"","overall_status":"COMPLETED","enrollment_count":124879,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT02987803","title":"Helping Mothers Select Better Childbirth Hospitals","phase":"NA","overall_status":"COMPLETED","enrollment_count":120621,"lead_sponsor_name":"Harvard School of Public Health (HSPH)","has_results":false},{"nct_id":"NCT00340353","title":"Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03918044","title":"Obesity Among Young Adult Males Born With Cesarean Section.","phase":"","overall_status":"COMPLETED","enrollment_count":97291,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04392388","title":"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis","phase":"","overall_status":"COMPLETED","enrollment_count":96883,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT04944329","title":"Hip Fracture and COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":73661,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT05047900","title":"The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community","phase":"NA","overall_status":"COMPLETED","enrollment_count":70000,"lead_sponsor_name":"Mahidol University","has_results":false},{"nct_id":"NCT04685668","title":"The PartoMa Project: Enabling Best Post Possible Childbirth Care in Tanzania.","phase":"NA","overall_status":"COMPLETED","enrollment_count":65181,"lead_sponsor_name":"University of Copenhagen","has_results":false},{"nct_id":"NCT04915781","title":"Tobacco Use and COVID-19 Incidence in the Finnish General Population","phase":"","overall_status":"COMPLETED","enrollment_count":60872,"lead_sponsor_name":"Finnish Institute for Health and Welfare","has_results":false},{"nct_id":"NCT01117168","title":"Enrollment on the Childhood Cancer Research Network (CCRN) of the Children's Oncology Group","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57816,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04378452","title":"Assessment of the Psycho-social Impact of COVID-19 Outbreak","phase":"","overall_status":"COMPLETED","enrollment_count":56656,"lead_sponsor_name":"Fundació Institut Germans Trias i Pujol","has_results":false},{"nct_id":"NCT06684080","title":"The Effectiveness of a Care Bundle to Prevent Postpartum Hemorrhage After Cesarean Delivery","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":52000,"lead_sponsor_name":"Dunjin Chen","has_results":false},{"nct_id":"NCT04664049","title":"The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":51000,"lead_sponsor_name":"National Research Institute of Chinese Medicine, Ministry of Health and Welfare","has_results":false},{"nct_id":"NCT04368728","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":46969,"lead_sponsor_name":"BioNTech SE","has_results":true},{"nct_id":"NCT04652102","title":"A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":39680,"lead_sponsor_name":"CureVac","has_results":true},{"nct_id":"NCT04611802","title":"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":33000,"lead_sponsor_name":"Novavax","has_results":false},{"nct_id":"NCT04516746","title":"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":32450,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04636697","title":"Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30918,"lead_sponsor_name":"Medicago","has_results":false},{"nct_id":"NCT04470427","title":"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":30415,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT07266558","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT05059106","title":"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":29637,"lead_sponsor_name":"Federal University of Espirito Santo","has_results":false},{"nct_id":"NCT04532411","title":"COVID-19 Testing Sample Acquisition Throughput and Efficiency","phase":"","overall_status":"COMPLETED","enrollment_count":28948,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT04847102","title":"A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":28000,"lead_sponsor_name":"Walvax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT04715607","title":"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens","phase":"NA","overall_status":"COMPLETED","enrollment_count":27947,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04401085","title":"COVID-19: Herd Immunity Study in the Czech Republic","phase":"","overall_status":"COMPLETED","enrollment_count":27000,"lead_sponsor_name":"Institute of Health Information and Statistics of the Czech Republic","has_results":false},{"nct_id":"NCT04411576","title":"Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare","phase":"","overall_status":"COMPLETED","enrollment_count":26326,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT05791630","title":"The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL)","phase":"NA","overall_status":"RECRUITING","enrollment_count":23650,"lead_sponsor_name":"Ostfold Hospital Trust","has_results":false},{"nct_id":"NCT03569735","title":"Nanshan Elderly Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07308314","title":"Taining Golden Lake Comprehensive Chronic Disease Management Initiative","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT03640702","title":"The Effect of Primary Cesarean Section Prevention on Maternal and Neonatal Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":20000,"lead_sponsor_name":"Rambam Health Care Campus","has_results":false},{"nct_id":"NCT00026754","title":"Eligibility Screening for the NIH Intramural Research Program Clinical Protocols","phase":"","overall_status":"COMPLETED","enrollment_count":19522,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04408014","title":"Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo","phase":"","overall_status":"COMPLETED","enrollment_count":18901,"lead_sponsor_name":"Butantan Institute","has_results":false},{"nct_id":"NCT04955626","title":"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":16372,"lead_sponsor_name":"BioNTech SE","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}